Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
This 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or
placebo to insulin in patients with Type 2 diabetes mellitus (non-insulin-dependent) who have
not achieved their blood glucose goal using insulin alone. This study requires a total of
seven visits during 28 weeks.